ClinicalTrials.gg
CompletedNCT03902522Updated Sep 16, 2025Results posted

PRO 140 in Treatment-Experienced HIV-1 Subjects

A Phase 2/3 interventional study of PRO 140 in HIV-1-infection, sponsored by CytoDyn, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by CytoDyn, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2018, registered Apr 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART (antiretroviral therapy) during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.

Read the detailed description

PRO 140, in combination with other antiretroviral agents, is indicated for treatment experienced adult HIV-1 patients infected with CCR5-tropic virus (virus that uses the chemokine receptor type 5 to enter the cell). These patients must demonstrate evidence of HIV-1 replication despite ongoing antiretroviral therapy and have documented genotypic or phenotypic resistance to at least one ART drug within three drug classes (or within two or more drug classes with limited treatment option). The options may be limited as a result of drug antiviral class cross-resistance, documented treatment intolerance, documented objective assessments such as renal or hepatic insufficiency (e.g. high creatinine at baseline, limiting treatment options due to potential for toxicity), past adverse reactions such as hypersensitivity reactions or neuropsychiatric issues that could limit use of currently approved drugs. Study population includes treatment-experienced HIV-infected patients with CCR5-tropic virus who demonstrates evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented genotypic or phenotypic resistance to ART drugs within three drug classes (or within two drug classes with limited treatment option). The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, age ≥18 years
  2. Exclusive CCR5-tropic virus at Screening Visit as determined by Monogram Biosciences Trofile® Assay
  3. Have a history of at least 3 months on current antiretroviral regimen
  4. Treatment-experienced -infected patients with documented genotypic or phenotypic resistance to at least one ART drug within three drug classes OR Treatment-experienced HIV-infected patients with documented genotypic or phenotypic resistance to at least one ART drug within two drug classes and have limited treatment option. The options may be limited as a result of drug antiviral class cross-resistance, documented treatment intolerance, documented objective assessments such as renal or hepatic insufficiency (e.g. high creatinine at baseline, limiting treatment options due to potential for toxicity), past adverse reactions such as reactions or neuropsychiatric issues that could limit use of currently approved drugs.
  5. Be willing to remain on treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure
  6. Plasma HIV-1 RNA ≥ 400 copies/mL at Screening Visit as determined by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Roche Taqman® Real-Time PCR) and documented detectable viral load (HIV-1 RNA >50 copies/ml) within the last 3 months prior to Screening Visit
  7. Laboratory values at Screening of:

    1. (ANC) ≥750/mm3
    2. (Hb) ≥10.5 gm/dL (male) or ≥ 9.5 gm/dL (female)
    3. ≥75,000 /mm3
    4. Serum (SGPT/ALT) \<5 x (ULN)
    5. Serum aspartate transaminase (SGOT/AST) \<5 x ULN
    6. (total) \<2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease
    7. Creatinine ≤1.5 x ULN
  8. Clinically normal resting 12-lead at Screening Visit or, if abnormal, considered not by the Principal Investigator
  9. Both male and female patients and their partners of must agree to use 2 medically accepted methods of (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug
  10. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written Note: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements

Exclusion criteria

Exclusion Criteria:

  1. Documented CXCR4-tropic virus or Dual/Mixed tropic (R5X4) virus as determined by -1 tropism assay
  2. Patients with no viable treatment options ( i.e., no fully active antiretroviral drug available which can be effectively combined to form a viable new OBT)
  3. Any active infection or requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma) Note: Subjects infected by the virus or virus will be eligible for the study if they have no signs of hepatic decompensation and meet the liver function tests eligibility criteria
  4. Laboratory test values of ≥ grade 3 DAIDS (Division of Acquired Immune Deficiency Syndrome) laboratory abnormality with the exception of the absolute criterion of \<200/mm3
  5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
  6. Unexplained fever or illness within 1 week prior to the first study dose
  7. Any vaccination within 2 weeks prior to the first study dose
  8. Subjects weighing \< 35kg
  9. History of anaphylaxis to oral or parenteral drugs
  10. History of Bleeding Disorder or patients on anti-coagulant therapy
  11. Participation in an experimental drug trial(s) within 30 days of the Screening Visit
  12. Any known allergy or antibodies to the study drug or
  13. Treatment with any of the following:

    1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit
    2. within 60 days prior to the screening visit
    3. Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the screening visit
    4. Oral or parenteral within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy >5 mg/day will be excluded with the following exception:

      • Subjects on inhaled, nasal, or topical steroids will not be excluded
  14. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Leronlimab (PRO 140)

    Subjects will be on existing ART for one week followed by PRO 140 700 mg weekly subcutaneous (SC) Inj. + existing ART for the next week. Subsequently, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.

    Drug: PRO 140

Interventions

  • 2 injections of PRO 140 (2 X 2 mL/inj.) Subjects who were previously enrolled and receiving 350 mg dose had the option to move to the 700mg dose for the remainder of the trial.

    Also known as: Leronlimab

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period

    The primary endpoint for this study is the proportion of participants with a ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline to the end of the initial 1-week treatment period.

    Time frame: 1-week from baseline to the end of the initial PRO 140 and ART treatment period

Secondary outcomes

  1. Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period

    The secondary endpoint is the proportion of participants with ≥ 1 log10 reduction in HIV-1 RNA viral load from baseline at the end of the initial 1-week treatment period

    Time frame: 1-week from baseline to the end of the initial PRO 140 and ART treatment period

  2. Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the Initial 1-week Treatment Period

    The secondary endpoint is the mean change between baseline and the end of the 1-week of treatment period in HIV-1 RNA levels (log10 copies/mL) (baseline was T1, mean change was calculated between time points T1 and T2). If the mean change is a negative value, this indicates a reduction in viral load.

    Time frame: 1-week from baseline to the end of the initial PRO 140 and ART treatment period

  3. Percentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 25

    The secondary endpoint is the percentage of participants achieving HIV-1 RNA \< 400 copies/mL at week 25

    Time frame: 25 weeks post-initiation of PRO 140 and existing ART treatment

  4. Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 25

    The secondary outcome measure is the percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 25

    Time frame: 25 weeks post-initiation of PRO 140 and existing ART treatment

  5. Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL)

    The secondary outcome measure is the mean change in HIV-1 RNA levels (log10 copies/mL) between Baseline (T1) and week 25 (T25). Baseline was T1, mean change was calculated between time points T1 and T25. If the mean change is a negative value, this indicates a reduction in viral load.

    Time frame: 25 weeks post-initiation of PRO 140 and existing ART treatment

  6. Mean Change From Baseline in CD4 Cell Count at the End of the Initial 1-week Treatment Period

    The secondary outcome measure is the mean change in CD4 cell count between Baseline and the end of the initial 1-week treatment period (T2). Baseline was T1, mean change was calculated between time points T1 and T2.

    Time frame: 1-week post-initiation of PRO 140 and ART treatment.

  7. Mean Change From Baseline in CD4 Cell Count at Week 23

    The secondary outcome measure is the mean change in CD4 cell count between Baseline (T1) and week 23 (T23)

    Time frame: 23 weeks post-initiation of PRO 140 and existing ART treatment

07

Results

Posted Sep 16, 2025
Limitations and caveats
According to the information provided by contract research organization (CRO), lab data for CD4 cell count was not collected at week 25. This outcome measure could not be reported in a data table.

Participant flow

Participant flow — Overall Study
MilestoneLeronlimab (PRO 140)
Started6
Completed5
Not completed1

Outcome measures

PrimaryProportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period

The primary endpoint for this study is the proportion of participants with a ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline to the end of the initial 1-week treatment period.

Time frame:
1-week from baseline to the end of the initial PRO 140 and ART treatment period
Reported as:
Number · proportion of participants
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period
proportion of participantsLeronlimab (PRO 140)
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period0.80
SecondaryProportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period

The secondary endpoint is the proportion of participants with ≥ 1 log10 reduction in HIV-1 RNA viral load from baseline at the end of the initial 1-week treatment period

Time frame:
1-week from baseline to the end of the initial PRO 140 and ART treatment period
Reported as:
Number · proportion of participants
Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period
proportion of participantsLeronlimab (PRO 140)
Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the Initial 1-week Treatment Period0.40
SecondaryMean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the Initial 1-week Treatment Period

The secondary endpoint is the mean change between baseline and the end of the 1-week of treatment period in HIV-1 RNA levels (log10 copies/mL) (baseline was T1, mean change was calculated between time points T1 and T2). If the mean change is a negative value, this indicates a reduction in viral load.

Time frame:
1-week from baseline to the end of the initial PRO 140 and ART treatment period
Reported as:
Mean · log10 copies per mL
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the Initial 1-week Treatment Period
log10 copies per mLLeronlimab (PRO 140)
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the Initial 1-week Treatment Period-0.69 ± 0.61
SecondaryPercentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 25

The secondary endpoint is the percentage of participants achieving HIV-1 RNA \< 400 copies/mL at week 25

Time frame:
25 weeks post-initiation of PRO 140 and existing ART treatment
Reported as:
Count of participants · Participants
Percentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 25
ParticipantsLeronlimab (PRO 140)
Percentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 255
SecondaryPercentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 25

The secondary outcome measure is the percentage of participants achieving HIV-1 RNA \< 50 copies/mL at week 25

Time frame:
25 weeks post-initiation of PRO 140 and existing ART treatment
Reported as:
Count of participants · Participants
Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 25
ParticipantsLeronlimab (PRO 140)
Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 253
SecondaryMean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL)

The secondary outcome measure is the mean change in HIV-1 RNA levels (log10 copies/mL) between Baseline (T1) and week 25 (T25). Baseline was T1, mean change was calculated between time points T1 and T25. If the mean change is a negative value, this indicates a reduction in viral load.

Time frame:
25 weeks post-initiation of PRO 140 and existing ART treatment
Reported as:
Mean · log10 copies/mL
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL)
log10 copies/mLLeronlimab (PRO 140)
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL)-2.29 ± 0.63
SecondaryMean Change From Baseline in CD4 Cell Count at the End of the Initial 1-week Treatment Period

The secondary outcome measure is the mean change in CD4 cell count between Baseline and the end of the initial 1-week treatment period (T2). Baseline was T1, mean change was calculated between time points T1 and T2.

Time frame:
1-week post-initiation of PRO 140 and ART treatment.
Reported as:
Mean · cells/uL
Mean Change From Baseline in CD4 Cell Count at the End of the Initial 1-week Treatment Period
cells/uLLeronlimab (PRO 140)
Mean Change From Baseline in CD4 Cell Count at the End of the Initial 1-week Treatment Period37.4 (-13 to 92)
SecondaryMean Change From Baseline in CD4 Cell Count at Week 23

The secondary outcome measure is the mean change in CD4 cell count between Baseline (T1) and week 23 (T23)

Time frame:
23 weeks post-initiation of PRO 140 and existing ART treatment
Reported as:
Mean · cells/uL
Mean Change From Baseline in CD4 Cell Count at Week 23
cells/uLLeronlimab (PRO 140)
Mean Change From Baseline in CD4 Cell Count at Week 23123 (3 to 254)

Adverse events

Collected over AEs and SAEs were assessed from T1 visit up to T25 visit (up to 32 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leronlimab (PRO 140) + Existing ART0/6 (0%)0/6 (0%)0/6 (0%)
Leronlimab (PRO 140) + OBT0/6 (0%)2/6 (33.3%)2/6 (33.3%)
Most frequent serious events
Most frequent serious events
EventLeronlimab (PRO 140) + Existing ARTLeronlimab (PRO 140) + OBT
Back PainMusculoskeletal and connective tissue disorders0/61/6
Myocardial infarctionCardiac disorders0/61/6
Most frequent other events
Most frequent other events
EventLeronlimab (PRO 140) + Existing ARTLeronlimab (PRO 140) + OBT
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/61/6
Back PainMusculoskeletal and connective tissue disorders0/61/6
EcchymosisSkin and subcutaneous tissue disorders0/61/6

Baseline characteristics

The Intent-to-Treat (ITT) population is defined as the set of subjects who are enrolled and have received at least one dose of PRO 140. Subjects who discontinue from the study prior to their first post-baseline assessment will be included in the ITT population and analyzed as non-responders in the primary safety analysis

Age, Categorical
Age, Categorical(Participants)Leronlimab (PRO 140)
<=18 years0
Between 18 and 65 years6
>=65 years0
Age, Continuous
Age, Continuous(Years)Leronlimab (PRO 140)
Mean52.7 (36 to 64)
Sex: Female, Male
Sex: Female, Male(Participants)Leronlimab (PRO 140)
Female2
Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Leronlimab (PRO 140)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Leronlimab (PRO 140)
United States6
Years since original HIV Diagnosis
Years since original HIV Diagnosis(Years)Leronlimab (PRO 140)
Mean27 (10 to 46)
08

Study locations

17 sites
  • CD02_OpenLabel Investigational Site
    Palm Springs, California 92262, United States
  • CD02_OpenLabel Investigational Site
    San Francisco, California 94115, United States
  • CD02_OpenLabel Investigational Site
    New Haven, Connecticut 06510, United States
  • CD02_OpenLabel Investigational Site
    Ft. Pierce, Florida 34982, United States
  • CD02_OpenLabel Investigational Site
    Miami, Florida 33136, United States
  • CD02_OpenLabel Investigational Site
    Miami, Florida 33139, United States
  • CD02_OpenLabel Investigational Site
    Miami, Florida 33169, United States
  • CD02_OpenLabel Investigational Site
    Orlando, Florida 32803, United States
  • CD02_OpenLabel Investigational Site
    West Palm Beach, Florida 33401, United States
  • CD02_OpenLabel Investigational Site
    Decatur, Georgia 30033, United States
  • CD02_OpenLabel Investigational Site
    Chicago, Illinois 60613, United States
  • CD02_OpenLabel Investigational Site
    Wichita, Kansas 67214, United States
  • CD02_OpenLabel Investigational Site
    Syracuse, New York 13210, United States
  • CD02_OpenLabel Investigational Site
    Bellaire, Texas 77301, United States
  • CD02_OpenLabel Investigational Site
    Houston, Texas 77004, United States
  • CD02_OpenLabel Investigational Site
    Houston, Texas 77098, United States
  • CD02_OpenLabel Investigational Site
    Spokane, Washington 99202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in May 2020, 22 months.

Results were first posted in Sep 2025, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2019
First posted
Apr 4, 2019
StartActual
Jun 25, 2018
Primary completionActual
May 18, 2020
CompletionActual
May 18, 2020
Results first posted
Sep 16, 2025
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03902522
Lead sponsor
CytoDyn, Inc.
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Apr 4, 2019
Start date
Jun 25, 2018
Primary completion
May 18, 2020
Completion
May 18, 2020
Results posted
Sep 16, 2025
Last update
Sep 16, 2025

Study contacts

Scott Kelly, MD
study chair · CytoDyn, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion